Trial site
Asahikawa Medical University Hospital
Asahikawa, Hokkaido, Japan 078-8510, JapanNot linked to an institution yet
- 13running trials
- 2closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 24 trials
- Phase 2/31 trial
- Status
- Active, not recruiting7 trials
- Recruiting5 trials
- Completed2 trials
- Not yet recruiting1 trial
- Lead sponsor
- Eli Lilly and Company3 trials
- Alumis Inc2 trials
- Janssen Research & Development, LLC2 trials
- Amgen1 trial
- Chiesi Farmaceutici S.p.A.1 trial
- and 6 more
Running trials
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044· Phase 2· Eli Lilly and Company· Source
Contact: Mikihiro Fujiya (principal investigator)
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Eli Lilly and Company· Source
Contact: Koji Sawada (principal investigator)
Active, not recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· Phase 3· Alumis Inc· Source
Recruiting
Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest
NCT06776549· Kagawa University· Source
Contact: Akihito Tampo (principal investigator)
Active, not recruiting
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06311721· Phase 3· Amgen· Source
Recruiting
Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease
NCT05710692· Phase 2/3· Chiesi Farmaceutici S.p.A.· Source
Contact: Naoki Nakagawa
Active, not recruiting
Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome
NCT05914155· Phase 3· Shoichi Maruyama MD PhD· Source
Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347· Medtronic Cardiovascular· Source
Contact: Daiki Uchida, MD, PhD (principal investigator)
Active, not recruiting
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
Japanese Idiopathic Interstitial Pneumonias Registry
NCT03041623· North East Japan Study Group· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error